TrialDiabetes technology & therapeutics2020

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.

Satish K Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.